Michael Styler is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 144 publications with 1,138 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Ave
Philadelphia, PA 19111
Telephone
215-728-2500Registry record last updated 7 Mar 2023.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20255 payments
- Adaptive Biotechnologies CorporationProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.7%Thalidomide Analog12.2%Lenalidomide53%Revlimid47%Part D<11 patientsKinase inhibitor10.7%Jakafi54%Imatinib Mesylate46%Part D<11 patients+ 2 more classes in this area
Dermatology
19.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.1%Acyclovir100%Part D≥17 patientsMetabolism & gastrointestinal
14.9%Serotonin-3 Receptor Antagonist10.7%Ondansetron Hcl100%Part D<11 patientsOpioid Agonist4.2%Loperamide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Using Oral Vancomycin As Prophylaxis Against Clostridioides Difficile Infection in Stem Cell Transplant Recipients Is Associated with Increased Gram Negative Bacteremia
Biology of Blood and Marrow Transplantation
2024 - MM-595 Feasibility and Safety of Outpatient Model for Teclistamab Step-Up Dosing Administration: A Single Center Experience
Clinical Lymphoma Myeloma & Leukemia
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
John Ridge, MD
Fox Chase Cancer Center
Eric Horwitz, MD
Fox Chase Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”